花粉曝露実験室を用いたスギ花粉症に対するフルチカゾンフランカルボン酸エステル点鼻薬の有用性に関する研究

概要

論文の詳細を見る
Fluticasone furoate (FF) is a potent topical glucocorticoid for the treatment of allergic rhinitis (AR). We studied the effect of FF on subjects with seasonal allergic rhinitis using an allergen challenge chamber (ACC). The investigation was conducted in 35 patients suffering from Japanese cedar pollinosis through a randomized parallel-group trial. We compared the nasal and ocular symptom scores between the control subjects and the treatment group. There were no statistical differences in background factors between the two groups. The aim of this study was to assess the efficacy of FF in the ACC. FF showed consistent attenuation of AR symptoms. A seven-day treatment course of intranasal FF given once-daily before the allergen exposure caused a statistically-significant reduction of some objective symptoms of AR including associated eye findings. In regard to subjective responses to eye manifestations, however, statistical significance for the treatment-control comparison was not be attained. The positive effects obtained by this study suggested that FF could be efficacious as a once daily steroid before the pollen allergy season. This means that FF could also be used for the initial drug of choice for the treatment of AR resulting from pollinosis along with oral anti-allergic agents.